Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2017

04.07.2017 | Editorial Commentary

A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy

verfasst von: Frederik A. Verburg, Markus Luster

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Excerpt

The erroneously named prostate specific membrane antigen (PSMA), also known by the functional description of glutamatedecarboxypeptidase 2, has in recent years seen a massive upsurge in interest in nuclear medicine due to the newly available specific functional substrate tracers for both positron emission tomography (PET) imaging and radionuclide therapy [1‐12]. Because of its superior characteristics [13‐15] PSMA targeted imaging and therapy has become part of routine clinical care in an almost unprecedented rapid adoption process and has replaced the previous clinical standard wherever the necessary facilities are available and regulations allow the use of PSMA targeted tracers before completion of the formal trials on efficacy and pharmaceutical registration procedures. …
Literatur
1.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.CrossRefPubMed
2.
Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94.CrossRefPubMed
3.
Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, et al. Comparison of [F]DCFPyL and [ Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575–84.CrossRefPubMedPubMedCentral
4.
Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829–36.CrossRefPubMed
5.
Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1794–800.CrossRefPubMedPubMedCentral
6.
Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36:582–7.CrossRefPubMed
7.
Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F, Behrendt FF, Verburg FA. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging 2016;43:1410–1417.
8.
Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Voo S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43:397–403.CrossRefPubMed
9.
Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114.PubMed
10.
Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;43:42–51.CrossRefPubMed
11.
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.CrossRefPubMed
12.
McCarthy M, Langton T, Kumar D, Campbell A. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur J Nucl Med Mol Imaging 2017; In Press.
13.
Mottaghy FM, Heinzel A, Verburg FA. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges? Eur J Nucl Med Mol Imaging. 2016;43:1397–9.CrossRefPubMed
14.
Mottaghy FM, Behrendt FF, Verburg FA. (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging. Eur J Nucl Med Mol Imaging. 2016;43:394–6.CrossRefPubMed
15.
Verburg FA, Pfestroff A. Imaging: PSMA PET-CT in initial prostate cancer staging. Nat Rev Urol. 2016;13:498–9.CrossRefPubMed
16.
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.CrossRefPubMed
17.
Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer. 2003;107:323–9.CrossRefPubMed
18.
Marchal C, Redondo M, Padilla M, Caballero J, Rodrigo I, Garcia J, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol. 2004;19:715–8.PubMed
19.
Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66.CrossRefPubMedPubMedCentral
20.
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.CrossRefPubMed
21.
Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.CrossRefPubMed
22.
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.PubMed
23.
Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [(68)Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622–3.CrossRefPubMed
24.
Damle NA, Tripathi M, Chakraborty PS, Sahoo MK, Bal C, Aggarwal S, et al. Unusual uptake of prostate specific tracer 68Ga-PSMA-HBED-CC in a benign thyroid nodule. Nucl Med Mol Imaging. 2016;50:344–7.CrossRefPubMed
25.
Derlin T, Kreipe HH, Schumacher U, Soudah B. PSMA expression in tumor Neovasculature endothelial cells of Follicular thyroid adenoma as identified by molecular imaging using 68Ga-PSMA ligand PET/CT. Clin Nucl Med. 2017;42:e173–4.CrossRefPubMed
26.
Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E. Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41:331–2.CrossRefPubMed
27.
Lutje S, Gomez B, Cohnen J, Umutlu L, Gotthardt M, Poeppel TD, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET/CT. Clin Nucl Med. 2017;42:20–5.CrossRefPubMed
28.
Sager S, Vatankulu B, Uslu L, Sonmezoglu K. Incidental detection of Follicular thyroid carcinoma in 68Ga-PSMA PET/CT imaging. J Nucl Med Technol. 2016;44:199–200.CrossRefPubMed
29.
Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: opening a new horizon in Management of Thyroid Cancer? Clin Nucl Med. 2016;41:e263–5.CrossRefPubMed
30.
Zacho HD, Nielsen JB, Dettmann K, Haberkorn U, Petersen LJ. Incidental detection of thyroid metastases from renal cell carcinoma using 68Ga-PSMA PET/CT to assess prostate cancer recurrence. Clin Nucl Med. 2017;42:221–2.CrossRefPubMed
31.
Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halac M, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2.CrossRefPubMed
32.
Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Preliminary results of prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma. Eur J Nucl Med Mol Imaging 2017; In Press.
Metadaten
Titel
A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy
verfasst von
Frederik A. Verburg
Markus Luster
Publikationsdatum
04.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3767-4

Weitere Artikel der Ausgabe 10/2017

European Journal of Nuclear Medicine and Molecular Imaging 10/2017 Zur Ausgabe

Editorial Commentary

SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

Original Article

[18]Fluorodeoxyglucose Positron Emission Tomography for the Textural Features of Cervical Cancer Associated with Lymph Node Metastasis and Histological Type

Original Article

Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI

Review Article

PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies

Original Article

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Editorial

Players of ‘hypoxia orchestra’ – what is the role of FMISO?